

**B. PACKAGE LEAFLET**

## **PACKAGE LEAFLET: INFORMATION FOR THE USER**

### **CELVAPAN suspension for injection**

Pandemic influenza vaccine (H1N1) (whole virion, Vero cell derived, inactivated)

#### **Read all of this leaflet carefully before you receive this vaccine.**

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or nurse.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.

#### **In this leaflet**

1. What Celvapan is and what it is used for
2. Before you receive Celvapan
3. How Celvapan is given
4. Possible side effects
5. How to store Celvapan
6. Further information

### **1. WHAT CELVAPAN IS AND WHAT IT IS USED FOR**

Celvapan is a vaccine to prevent pandemic influenza (flu).

Pandemic flu is a type of influenza that occurs every few decades and which spreads rapidly around the world. The symptoms of pandemic flu are similar to those of an ordinary flu but may be more severe.

When a person is given the vaccine, the immune system (the body's natural defense system) will produce its own protection (antibodies) against the disease. None of the ingredients in the vaccine can cause flu.

### **2. BEFORE YOU RECEIVE CELVAPAN**

#### **You should not receive Celvapan**

- if you previously had a sudden life-threatening allergic reaction to any ingredient of Celvapan or to any of the substances that may be present in trace amounts as follows: formaldehyde, benzonase, sucrose.  
Signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue. However, in a pandemic situation, it may be appropriate for you to have the vaccine provided that appropriate medical treatment is immediately available in case of an allergic reaction.

If you are not sure, talk to your doctor or nurse before having this vaccine.

#### **Take special care with Celvapan**

- if you have had any allergic reaction other than a sudden life-threatening allergic reaction to any ingredient contained in the vaccine, to formaldehyde, benzonase, or to sucrose. (see section 6. Further information).

- if you have a severe infection with a high temperature (over 38°C). If this applies to you then your vaccination will usually be postponed until you are feeling better. A minor infection such as a cold should not be a problem, but your doctor or nurse should advise whether you could still be vaccinated with Celvapan,
- if you are having a blood test to look for evidence of infection with certain viruses. In the first few weeks after vaccination with Celvapan the results of these tests may not be correct. Tell the doctor requesting these tests that you have recently been given Celvapan,

In any of these cases, **TELL YOUR DOCTOR OR NURSE**, as vaccination may not be recommended, or may need to be delayed.

Please inform your doctor or nurse if you have a bleeding problem or bruise easily.

### **Taking other medicines**

Please tell your doctor or nurse if you are taking or have recently taken any other medicines, including medicines obtained without a prescription or have recently been given any other vaccine.

There is no information on administration of the vaccine Celvapan with other vaccines. However, if this cannot be avoided, the vaccines should be injected into separate limbs. In such cases, you should be aware that the side effects may be more intense.

### **Pregnancy and breast-feeding**

Tell your doctor if you are pregnant, think you may be pregnant, or plan to become pregnant. You should discuss with your doctor whether you should receive Celvapan.

The vaccine may be used during breast-feeding.

### **Driving and using machines**

Some effects mentioned under section 4. "Possible side effects" may affect your ability to drive or use machines.

## **3. HOW CELVAPAN IS GIVEN**

Your doctor or nurse will administer the vaccine in accordance with official recommendation. The vaccine will be injected into a muscle (usually in the upper arm).

#### **Adults and elderly**

A dose (0.5 ml) of the vaccine will be given.

A second dose of the vaccine should be given after an interval of at least three weeks.

#### **Children and adolescents aged 6 months to 17 years of age**

If it is considered that you or your child needs to be vaccinated, you/he/she may receive one dose of 0.5 ml vaccine and a second dose of 0.5 ml at least three weeks later.

#### **Children aged less than 6 months**

Vaccination is not currently recommended in this age group.

When Celvapan is given for the first dose, it is recommended that Celvapan (and not another vaccine against H1N1) be given for the complete vaccination course.

#### 4. POSSIBLE SIDE EFFECTS

Like all medicines, Celvapan can cause side effects, although not everybody gets them.

Allergic reactions may occur following vaccination, in rare cases leading to shock. Doctors are aware of this possibility and have emergency treatment available for use in such cases.

In the clinical studies with a similar vaccine, most side effects were mild in nature and short term. The side-effects are generally similar to those related to the seasonal flu vaccine. There were fewer side effects after the second vaccination compared with the first. The most frequently occurring side effect was injection site pain, which was usually mild.

The frequency of possible side effects listed below is defined using the following convention:

very common (affects more than 1 user in 10)

common (affects 1 to 10 users in 100)

uncommon (affects 1 to 10 users in 1,000)

rare (affects 1 to 10 users in 10,000)

very rare (affects less than 1 user in 10,000)

The side effects listed below have occurred with Celvapan (H5N1) in clinical studies in adults, including the elderly:

##### Very common:

- pain at the injection site

##### Common:

- runny nose and sore throat,
- headache, dizziness, vertigo (motion sickness)
- sweating more than usual,
- joint or muscle pain,
- chills, fatigue (feeling tired), malaise (generally feeling unwell), fever,
- tissue hardening, redness, swelling or bruising at the injection site

##### Uncommon:

- swollen glands,
- insomnia (difficulty sleeping), restlessness,
- impaired perception of touch, pain, heat and cold, sleepiness,
- conjunctivitis (an inflammation of the eye),
- sudden hearing loss,
- reduced blood pressure,
- shortness of breath, cough, congestion of the nose,
- nausea, vomiting, diarrhoea, stomach pain,
- rash, itching,
- irritation at the injection site

These side effects usually disappear within 1-2 days without treatment. If they persist, CONSULT YOUR DOCTOR.

From ongoing clinical trials, where a first dose of Celvapan (H1N1) was given to a limited number of adults, elderly and children similar adverse events were observed in the first days after vaccination to those previously seen with Celvapan (H5N1) vaccine.

The side effects listed below have occurred in the days or weeks after vaccination with vaccines given routinely every year to prevent flu. These side effects may occur with Celvapan.

##### Uncommon:

- generalised skin reactions including urticaria (hives)

Rare:

- Allergic reactions leading to a dangerous decrease of blood pressure, which, if untreated, may lead to shock. Doctors are aware of this possibility and have emergency treatment available for use in such cases.
- Fits
- Severe stabbing or throbbing pain along one or more nerves
- Low blood platelet count which can result in bleeding or bruising

Very rare:

- vasculitis (inflammation of blood vessels which can cause skin rashes, joint pain and kidney problems)
- neurological disorders such as encephalomyelitis (inflammation of the central nervous system), neuritis (inflammation of nerves) and a type of paralysis known as Guillain-Barré Syndrome

If any of these side effects occur, please tell your doctor or nurse immediately.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.

## **5. HOW TO STORE CELVAPAN**

Keep out of the reach and sight of children.

Do not use Celvapan after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.

Store in a refrigerator (2°C - 8°C).

Store in the original package in order to protect from light.

Do not freeze.

After first opening the vial is to be used within a maximum of 3 hours.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

## **6. FURTHER INFORMATION**

### **What Celvapan contains**

Active substance:

Whole virion influenza vaccine, inactivated, containing antigen of pandemic strain\*:

A/California/07/2009 (H1N1)                      7.5 micrograms\*\*  
per 0.5 ml dose

\* propagated in Vero cells (continuous cell line of mammalian origin)

\*\* haemagglutinin

This vaccine complies with the WHO recommendation and EU decision for the pandemic.

Other ingredients:

The other ingredients are: trometamol, sodium chloride, water for injections, polysorbate 80.

**What Celvapan looks like and contents of the pack**

Celvapan is an off-white, opalescent, translucent liquid.

One pack of Celvapan contains 20 multidose vials of 5 ml suspension for injection for 10 doses.

**Marketing Authorization Holder:**

Baxter AG  
Industriestrasse 67  
A-1221 Vienna  
Austria

**Manufacturer:**

Baxter AG  
Uferstrasse 15  
A-2304 Orth/Donau  
Austria

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder given below:

**België/Belgique/Belgien**

Baxter Belgium SPRL  
Bd. de la Plaine/Pleinlaan 5  
B-1050 Brussel/Bruxelles/Brüssel  
Tél/Tel: + 32 2 650 1711

**Luxembourg/Luxemburg**

Baxter Belgium SPRL  
Bd. de la Plaine/Pleinlaan 5  
B-1050 Bruxelles/Brüssel  
Tél/Tel: + 32 2 650 1711

**България**

ТП Бакстер АД  
ул. Рачо Димчев 4  
София 1000  
тел.: + 359 2 9808482

**Magyarország**

Baxter Hungary Kft  
Népfürdő u. 22.  
H-1138 Budapest  
Tel.: +361 202 19 80

**Česká republika**

Baxter Czech spol.s r.o.  
Opletalova 55  
CZ-110 00 Praha 1  
Tel.: +420 225774111

**Malta**

Baxter Healthcare Ltd  
Wallingford Road, Compton Newbury  
Berkshire RG20 7QW - UK  
Tel.: + 44 1635 206345

**Danmark**

Baxter A/S  
Gydevang 43  
DK-3450 Allerød  
Tlf: + 45 48 16 64 00

**Nederland**

Baxter B.V.  
Kobaltweg 49  
NL-3542 CE Utrecht  
Tel: + 31 30 2488911

**Deutschland**

Baxter Deutschland GmbH  
Edisonstraße 4  
D-85716 Unterschleißheim  
Tel: + 49 89 31701-0

**Norge**

Baxter AS  
Gjerdrumsvei 11  
N-0484 Oslo  
Tlf: + 47 22 58 4800

**Eesti**

AS Oriola  
Kungla 2  
EE-76505 Saue  
Tel.: + 372 6 515 100

**Ελλάδα**

Baxter (Hellas) E.Π.Ε.  
Εθνάρχου Μακαρίου 34 & Αθηνοδώρας  
Ηλιούπολη  
GR-163 41 Αθήνα  
Τηλ.: +30-210-99 87 000

**España**

Baxter S.L.  
Pouet de Camilo, 2  
E- 46394 Ribarroja del Turia (Valencia)  
Tel: + 34 96 2722800

**France**

Baxter SAS  
6 Avenue Louis Pasteur  
F-78310 Maurepas  
Tél: + 33 1 3461 5050

**Ireland**

Baxter Healthcare Ltd  
Unit 7 Deansgrange Industrial Estate  
IRL-Blackrock, Dublin  
Tel: + 44 1635 206345

**Ísland**

Icepharma hf.  
Lynghálsi 13  
IS-110 Reykjavík  
Sími: + 354 540 80-00

**Italia**

Baxter S.p.A.  
Piazzale dell'Industria, 20  
I-00144 Roma  
Tel: + 39 06 324911

**Κύπρος**

Baxter (Hellas) E.Π.Ε.  
Εθνάρχου Μακαρίου 34 & Αθηνοδώρας  
Ηλιούπολη  
GR-163 41 Αθήνα  
Τηλ.: +30-210-99 87 000

**Österreich**

Baxter Vertriebs GmbH  
Landstraßer Hauptstraße 99 /Top 2A  
A-1031 Wien  
Tel.: +43 1 71120 0

**Polska**

Baxter Polska Sp. z o.o.  
ul. Kruczkowskiego 8  
PL-00-380 Warszawa  
Tel.: + 48 22 4883 777

**Portugal**

Baxter Médico Farmacêutica Lda  
Sintra Business Park  
Zona Industrial da Abrunheira, Edifício 10  
P-2710-089 Sintra  
Tel: + 351 21 925 25 00

**România**

FARMACEUTICA REMEDIA S.A.  
78 Metalurgiei Blv., 4th district  
041836 Bucharest, ROMANIA  
Tel.: + 40-21-321 1640

**Slovenija**

Baxter d.o.o.  
Železna cesta 18  
1000 Ljubljana  
Tel.: + 386 1 420 16 80

**Slovenská republika**

Baxter AG, o. z.  
Dúbravská cesta 2  
SK-841 04 Bratislava  
Tel: + 421 2 59418455

**Suomi/Finland**

Baxter Oy  
PL 270  
Valimotie 15 A  
FIN-00381 Helsinki  
Puh/Tel: + 358 9 8621111

**Sverige**

Baxter Medical AB  
Torshamnsgatan 35  
Box 63  
S-164 94 Kista  
Tel: + 46 8 6326400

**Latvija**

Baxter AG Latvijas filiāle  
Dzelzavas iela 117  
LV 1021 RĪGA  
Tel.: +371 67784784

**United Kingdom**

Baxter Healthcare Ltd  
Wallingford Road, Compton Newbury  
Berkshire RG20 7QW - UK  
Tel: + 44 1635 206345

**Lietuva**

UAB TAMRO atstovybė  
S. Žukausko g. 29-1  
LT-09129 Vilnius  
Tel.: + 370 5 269 16 91

This leaflet was approved in

This medicine has been authorised under “Exceptional Circumstances”. The European Agency (EMA) will regularly review any new information on the medicine and this package leaflet will be updated as necessary.

Detailed information on this medicine is available on the European Medicines Agency (EMA) web site: <http://www.ema.europa.eu/>.

---

The following information is intended for medical or health care professionals only:

Prior to administration, the vaccine should be allowed to reach room temperature and the vial should be shaken well.

After first opening, the vial is to be used within a maximum of 3 hours.

Each vaccine dose of 0.5 ml is withdrawn into a syringe for injection.

The vaccine should not be administered intravascularly.

Any unused vaccine or waste material should be disposed of in accordance with local requirements.